Hematopoietic stem cell therapy for malignant diseases.
Allogeneic bone marrow or blood stem cell transplantation (SCT) has changed its face in the last two decades. The introduction of nonmyeloablative conditioning regimens has reduced procedure toxicity and allowed the application of SCT in patients and conditions in which SCT was not offered in the past. In this review we will summarize the changes and accomplishments achieved in the past years in the field of stem cell transplantation for malignant disorders.
Shapira
Michael Y
MY
Department of Bone Marrow Transplantation & Cancer Immunotherapy, Hadassah University Hospital, Jerusalem 91120, Israel. shapiram@hadassah.org.il
Hai
Ali Abdul
AA
Tsirigotis
Panagiotis
P
Resnick
Igor B
IB
Or
Reuven
R
Slavin
Shimon
S
D006086:Graft vs Host Disease / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods* / Q000639:trends*; D006801:Humans; D019172:Transplantation Conditioning / Q000379:methods